Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis by Chao-Sung Chang et al.
Chang et al. BMC Health Services Research 2012, 12:359
http://www.biomedcentral.com/1472-6963/12/359RESEARCH ARTICLE Open AccessTrends in the treatment changes and medication
persistence of chronic myeloid leukemia in
Taiwan from 1997 to 2007: a longitudinal
population database analysis
Chao-Sung Chang1,2, Yi-Hsin Yang3,4, Chien-Ning Hsu5,6* and Min-Ting Lin2Abstract
Background: Few studies have examined the longitudinal changes in the patterns, selection, and utilization of
treatments for chronic myeloid leukemia (CML) in routine clinical practice since the introduction of imatinib.
Therefore, we investigated the trends in CML therapy, including changes, patterns, and persistence to imatinib
therapy among patients with newly diagnosed CML.
Methods: We conducted a cross-sectional and longitudinal analysis of 11 years of claims data for patients with
newly diagnosed CML included in the Taiwan National Health Insurance program. Pharmacy and diagnosis claims
for newly diagnosed CML recorded between 1997 and 2007 year were extracted from the database. Annual overall
use, new use of CML therapy, and persistence to imatinib therapy were estimated. The Anatomical Therapeutic
Chemical codes for CML therapy [i.e., imatinib and conventional therapy: busulfan, hydroxyurea, interferon-α (IFNα),
and cytarabine], and the process code for hematopoietic stem cell transplantation were used to categorize
treatment patterns. Associations with patients characteristics were analyzed by multivariate logistic regression.
Results: Overall, the proportion of patients with newly diagnosed CML to all patients with CML increased by
approximately 4-fold between 1998 and 2007. There were steady increases in the proportions of all treated patients
and those starting therapy from 2003 to 2007. Fewer comorbid conditions and lower severity of CML were
associated with treatment initiation. Medication persistence varied according to treatment duration, as 38.7%
patients continued imatinib for ≥ 18 months without interruption but only 7.7% continued imatinib for ≥ 5 years.
Factors associated with persistence to imatinib therapy were removal of the need for prior authorization for
imatinib, and prior use of hydroxyurea and IFNα, whereas having undergone hematopoietic stem cell
transplantation led to reduced likelihood of persistence to imatinib therapy.
Conclusion: Treatment decisions for patients with CML changed over time in routine clinical practice. Our findings
suggest that clinicians are increasingly adopting the recommendations of international treatment guidelines for
CML. However, persistence to imatinib therapy is still substantially below the recommended level based on current
evidence for its efficacy. Our study also highlights the need to improve treatment persistence and effectiveness of
imatinib over the long term.
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Treatment guidelines established in 1998 recommend
that chronic myeloid leukemia (CML) should be treated
with conventional chemotherapy, interferon (IFN), or
hematopoietic stem cell transplantation (HSCT) [1].
Although HSCT is considered a curative treatment for
CML, patient eligibility, risk of early treatment-related
mortality, and long-term debility because of chronic
graft-versus-host disease have limited its application
[2,3]. The treatment strategy for CML has changed sub-
stantially over the last decade following the introduction
of specific targeted tyrosine kinase inhibitors (TKIs),
with imatinib being one of the notable achievements in
this class [4]. Imatinib is now widely used as first-line
therapy for Philadelphia chromosome-positive CML in
chronic phase (CP), accelerated phase (AP), and blast
crisis (BC) based on the results of several clinical trials
[5-7]. In addition, an 8-year update of the International
Randomized Study of Interferon vs. STI571 (IRIS) trial
demonstrated the durable efficacy of imatinib, as 55%
(304/553) of the patients treated with imatinib were still
on therapy at 8 years [8]. However, there is no information
on medication interruption or duration of therapy beyond
8 years. It is also unclear whether the patterns of imatinib
therapy in clinical trials were reflected by prescribers’
decision-making and the choice of therapy for CML in
routine clinical practice.
Knowledge about the impact of imatinib on the types
and patterns of treatments used to manage CML can
help health planners to develop or refine their own re-
imbursement policies to optimize CML care. There are
several advantages of using Taiwanese data to quantify
treatment utilization and examine a drug’s potential
public health impact. First, Taiwan provides universal
health insurance coverage. The National Health Insurance
(NHI) program offers a comprehensive benefits package,
which includes reimbursement for prescription drugs,
hospital care, and physician visits. Second, the system
maintains a database that records claims and reimburse-
ments for health services, and allows us to monitor the
impact of adopting new drugs on resource utilization and
quality of care. Finally, CML-related health services,
including hospitalization, physician visits, and prescriptions,
are fully reimbursed by the NHI program. Consequently,
insured patients do not incur any out-of-pocket expenses
for imatinib or CML therapy. In 2009, the Taiwan NHI
program spent TW $12 billion (approximately US $4
million) on imatinib expenditure, which was ranked
within the 10 highest amounts spent on individual drugs
in that year. Therefore, it is important to examine the
patterns of imatinib use in routine clinical practice from
a payer perspective. Consequently, the objectives of this
study were to determine the longitudinal trends in CML
therapy, explore the patterns of use and medicationpersistence to imatinib, and identify possible demographic
factors influencing its use in patients with newly diagnosed
CML enrolled in Taiwan’s NHI program.
Methods
Study design
We conducted a cross-sectional study of patients with
newly diagnosed CML enrolled in the Taiwan NHI
program to estimate the proportion of patients treated
for CML over 10 consecutive years. CML therapies
included HSCT and regimens commonly used to treat
CML-CP, including imatinib, busulfan, hydroxyurea, and
IFNα with or without cytarabine (Ara-C). To analyze
persistence to imatinib therapy, we identify treatment-
naïve patients and tracked them from the date of start-
ing treatment (index date) until the any of the following:
death in hospital, transfer to hospice services, HSCT, or
the end of the study period (December 2007), whichever
came first.
Data source
All data were retrieved from the National Health Insurance
Research Database (NHIRD) provided by the Bureau of
National Health Insurance (BNHI), Department of Health,
Taiwan. The National Health Research Institutes (NHRI)
maintains the health claims database, including registration
files and original inpatient, outpatient, and pharmacy
claims within the NHI program. These data files are de-
identified by scrambling the identification codes of both
patients and medical facilities. The NHIRD adheres to the
Computer-Processed Personal Data Protection Law and
related regulations of the BNHI and the NHRI [9].
Health insurance claims data used in this study repre-
sented actual payments made to the NHI program between
January 1, 1997, and December 31, 2007. Because the NHI
provides compulsory enrollment and has a high coverage
rate (99.3% in 2007), all census regions were considered to
be well represented over time in the database [10].
The study was approved by the Institutional Review
Board at Chung-Ho Memorial Hospital, Kaohsiung
Medical University.
Study population
We first identified all individuals with at least one claim
associated with a diagnosis of CML-CP (International
Classification of Disease Version 9 Clinical Modification
[ICD9-CM] code 205.1x) for inpatient or outpatient
claims submitted between 1997 and 2007. Newly diag-
nosed CML was defined as (1) previously undiagnosed
CML-CP; (2) previously undiagnosed CML-AP/BC, or
history of remission; (3) previously undiagnosed acute
leukemia; or (4) no prior CML therapy, including HSCT,
imatinib, busulfan, hydroxyurea, and IFNα with or without
Ara-C. We do not report CML therapy for 1997 because
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not available in this database. The high severity category in
the Medstat Disease Staging Clinical Criteria Version 5.24
was used as a proxy for patients with CML-AP/BC [11].
Study measures
Utilization of CML therapy
The utilization of CML therapy was determined from
pharmacy claims using the Anatomical of Therapeutic
Chemical codes for imatinib, conventional regimens
(i.e., busulfan, hydroxyurea, IFNα, and Ara-C), and the
procedure codes for HSCT. Drug utilization during
hospitalization and in outpatient settings during each
calendar year was retrieved for patients with newly
diagnosed CML-CP.
Annual CML therapy utilization was calculated as the
proportion of patients with newly diagnosed CML with
at least one claim for CML therapy or HSCT, including
those who were ‘ever treated’ during each calendar year.
To determine trends in treatment patterns, the proportions
of patients who started treatment for CML were catego-
rized into three groups: HSCT (exclusively to imatinib),
imatinib (exclusively to HSCT), and CML conventional
therapy (busulfan, hydroxyurea, IFNα, and Ara-C, alone or
in combination).
Accordingly, the annual proportion of patients starting
CML therapy was determined for patients with newly
diagnosed CML with a first claim for a CML regimen or
HSCT in each calendar year. We next identify demo-
graphic factors associated with the longitudinal trends in
treatment utilization and retrieved the following factors
from the database: patient characteristics at baseline,
including age at diagnosis, sex, year of CML diagnosis
classified as before or after the introduction of imatinib
in Taiwan (before 2004 vs 2004 or later), CML severity
(i.e., low, moderate, or high, based on the Medstat algo-
rithm) at 4 months after CML diagnosis, and Charlson
Comorbidity score (CCS) for comorbidities 1 year before
CML diagnosis. These factors were determined for newly
diagnosed patients before the approval of imatinib (1998),
at removal of the prior authorization request for imatinib
(2004), and after full access to imatinib use (2007). We also
determined the effect of insurance coverage on the start
of imatinib therapy [12] using multivariate logistic re-
gression in which we determined the likelihood of
receiving imatinib according to patient characteristics at
baseline in 1998, 2004, and 2007.
Patterns of imatinib prescription
Patterns of imatinib prescription were defined according
to the mean starting dose, time of starting imatinib, time
of discontinuation, and prior use of CML therapy. The
mean starting dose (mg/day) was calculated as the num-
ber of pills taken (converted into mg; ×100 mg/tablet)divided by the length of time (days) between the first
two consecutive claims. Only patients starting imatinib
with at least two claims for imatinib therapy were
analyzed; the starting daily dose was not calculated in
patients with a single claim throughout the study period.
The time between CML diagnosis and starting imatinib
therapy was calculated in months. Discontinuation was
defined as the last day of a 30-day supply of imatinib in
the last recorded claim. Treatment duration was calculated
as the time from starting imatinib therapy (index date) to
the date of discontinuation. Prescriptions extending
beyond the end of the follow-up were truncated at the last
day of the follow-up period.
Medication persistence
Medication persistence was measured as the duration of
initial imatinib therapy without interruption [13]. Medi-
cation interruption was defined as a gap of ≥ 60 days
between imatinib claims with the assumption that
patients could refill their imatinib prescription within
30 days from the run-out date of the previous prescription
refill without compromising treatment outcomes. The
duration of initial imatinib therapy without interruption
was calculated the time from the index date to the run-
out date of the last claim (the date of the last claim plus
30 days) before an interruption. Previously with newly
diagnosed CML-CP who failed imatinib therapy were
identified as those fulfilling one or more of the following
criteria: no complete hematologic response after 3 months
of initial therapy, no major cytogenetic response after
6 months of therapy, no complete cytogenetic response
after 18 months of therapy, hematologic or cytogenetic
relapse at any time, progression to CML-AP or CML-BC
at any time, treatment discontinuation, or HSCT [14,15].
To provide better insight into medication persistence
within 18 months of starting therapy in real world settings,
the duration of initial imatinib therapy without interruption
was classified as < 18 months (non-persistent) and ≥ 18
months (persistent). Multivariate logistic regression was
used to estimate the likelihood of treatment persistence
according to patient characteristics at baseline, prior treat-
ment, time of starting imatinib therapy, mean starting dose
of imatinib, treatment duration, and HSCT during the
follow-up period. Data management and analyses were
conducted using SAS Version 9.1 (Cary, NC).
Results
Patient characteristics
Our analysis sample consisted of 2,672 patients, after
excluding patients with a history of remission, advanced
CML, acute leukemia, or CML therapy before the diag-
nosis of CML-CP. The estimated annual incidence of
CML in the study population was 1.2 cases per 100,000
persons (standard deviation = 0.2) between 1998 and
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(SD = 0.1) between 2003 and 2007. The mean age at diag-
nosis was 55.7 ± 20.4 years; 1,264 patients were > 60 years
old (47.3%). Overall, there were more men than women
with newly diagnosed CML (60.8% and 39.2%, respec-
tively). Based on the Medstat algorithm, the severity of
CML was graded as high, moderate, and low in 12.4%,
72.2%, and 2.1%, respectively; CML severity was missing in
13.3%. Over half of the patients (53.8%) had at least one
comorbidity (CCS ≥ 1).
CML therapy
Figure 1 presents the longitudinal changes in CML
therapy. The proportion of patients undergoing HSCT
decreased gradually over the 10-year period from 3% in
1999 to 1% in 2007. The proportion of patients treated
with imatinib increased from 12% in 2002 to 36% in
2007. The proportion of patients treated with conven-
tional CML therapies (i.e., hydroxyurea, busulfan, IFNα,
and Ara-C alone or in combination) was determined for
three different periods, 1998–2001 (the rate decreased
slightly from 14% to 10%), 2002–2003 (the rate increased
slightly from 41% to 45%), and 2004–2007 (the rate
decreased significantly from 38% to 25%). The most
commonly used conventional therapy was hydroxyurea
followed by IFNα with/without Ara-C and busulfan.
Figure 2 shows the trends in initial treatment type for
CML. The proportion of patients receiving new CML
therapy increased approximately 4-fold over the 10-year
period (from 42 of 281 in 1998 to 156 of 258 in 2007).
Imatinib became a dominate treatment when the need
for prior authorization was stopped in 2004. The use ofFigure 1 CML therapy overall use in patients with newly diagnosed Cconventional regimens tended to increase between 2002
and 2003, but then declined following broad access to
imatinib.
As indicated in Table 1, we found temporal changes in
the associations between patient demographic factors
and the start of treatment for CML. Patients > 40 years
old were less likely than younger patients to start CML
therapy before (i.e., in 1998) and after the introduction
of imatinib (i.e., 2004 and 2007). There was no difference
between males and females in the likelihood of receiving
therapy. Patients with a comorbidity were more likely to
receive therapy than patients without a comorbidity in
1998 [odds ratio (OR), 1.2; 95% confidence interval (CI),
0.6–2.4]. However, following the introduction of imati-
nib, there was a trend towards a reduced likelihood of
starting treatment among patients with a comorbidity in
2004 (OR, 0.6; 95% CI, 0.4–1.2) and 2007 (OR, 0.4; 95%
CI, 0.2–0.6). Similarly, the presence of advanced CML
decreased the likelihood starting therapy in the same
year of diagnosis in 1998 (OR, 4.3; 95% CI, 2.0–9.3),
2004 (OR, 2.1; 95% CI, 0.8–5.4) and 2007 (OR, 2.3; 95%
CI, 1.1–5.1), although the level of significance was not
maintained throughout this period.
Patterns and persistence of imatinib therapy
The mean age of patients starting imatinib therapy
(n = 782) was 47.8 years. Approximately 60% of these
recipients were male, 49.4% were diagnosed with CML in
2002 or later, and 43% had at least one comorbidity. The
severity of CML was high in 12.4% of patients. Overall,
72% of the patients had been treated with hydroxyurea,
18% with IFNα/Ara-C, and 2.2% with busulfan beforeML per calendar year (1998-2007).
Figure 2 CML therapy new use in patients with newly diagnosed CML per calendar year (1998-2007).
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starting imatinib therapy was 3.1 months (mean 14.6 ±
19.5 months). In most patients (73%), the starting dose
was 300–400 mg/day, while 16.3% started at a dose ≤
300 mg/day, and 10.7% started at a dose ≥ 400 mg/day.
The mean ± SD duration of imatinib treatment was 26.1
± 19.9 months, and ranged from 1 to 69.8 months. With
over 5 years of follow-up data (range, 0.2–69 months),Table 1 Associations between receiving Chronic Myeloid Leuk
characteristics
Characteristics 1998a
n (%) χ2 OR p n (%)
(p-value) (95%CI)b (
Age at diagnosis, years
≥40 228 (81.1) 9.16 (<0.01) 0.4 (0.2-0.8) <0.01 160 (74.4) 6
<40 53 (18.9) 1 (referent) 55 (25.6)
Gender
Male 166 (59.1) 0.00 (0.95) 0.8 (0.4-1.7) 0.60 126 (58.6) 1
Female 115 (40.9) 1 (referent) 89 (41.4)
Charlson comorbidity score
≥1 101 (35.9) 0.00 (0.97) 1.2 (0.6-2.4) 0.71 118 (54.9) 3






4.3 (2.0-9.3) <0.001 28 (13.0) 1
less
severity c
236 (84.0) 1 (referent) 187 (87.0)
a. 1998 (beginning of study, n = 281); 2004 (end of prior authorization request for im
b. OR = odds ratio, each OR of the variable was adjusted by the other factors in the
c. Less severity, including moderate, low severity or missing relevant severity informimatinib therapy was discontinued in 269 (34.4%)
patients. Reasons for discontinuation included HSCT
(3%), death/transfer to hospice services (7.7%), disenroll-
ment and/or end of follow-up (19.4%), and unknown
reasons (4.6%). Approximately one-third of patients
(33.4%) received imatinib for < 1 year, 20% for 1–2 years,
13.4% for 2–3 years, 17.1% for 3–4 years, 8.6% for 4–5 years,
and 7.7% for > 5 years.emia (CML) treatment initiation and patient
2004 2007
χ2 OR p n (%) χ2 OR p
p-value) (95%CI) (p-value) (95%CI)
.30 (0.01) 0.5 (0.2-0.9) 0.03 186 (72.1) 16.86
(<.0001)
0.4 (0.2-0.7) <0.01
1 (referent) 72 (27.9) 1 (referent)
.25 (0.26) 0.7 (0.4-1.3) 0.26 151 (58.5) 0.49 (0.49) 1.4 (0.8-2.3) 0.29
1 (referent) 107 (41.5) 1 (referent)
.71 (0.05) 0.6 (0.4-1.2) 0.13 140 (54.3) 20.36
(<.0001)
0.4 (0.2-0.6) <0.001
1 (referent) 118 (45.7) 1 (referent)
.64 (0.20) 2.1 (0.8-5.4) 0.12 40 (15.5) 2.87 (0.09) 2.3 (1.1-5.1) 0.04
1 (referent) 218 (84.5) 1 (referent)
atinib use, n = 215); 2007 (end of study, n = 258).
logistic regression model.
ation (unknown).
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of imatinib use for persisting and non-persisting patients.
Overall, 38.7% (n = 303) of patients were defined as persist-
ent in their initial treatment period. Patients diagnosed with
CML after the withdrawal of imatinib prior authorization
(2004 or later) (OR, 4.1; 95% CI, 2.2–7.9), previously
treated with hydroxyurea (OR, 1.8; 95%CI, 1.1–2.8) and
IFNα or Ara-C (OR, 1.9; 95% CI, 1.1–3.3), and longer
duration of imatinib therapy (OR,1.1; 95% CI, 1.09–1.13)
were significantly associated with an increased likelihood
of persistence to imatinib therapy. Patients undergoing
late HSCT were less likely to persist with initial imatinib
therapy (OR, 0.1; 95% CI, 0.02–0.50).
Discussion
The results of this study provide important insight into
the status of CML therapy in Taiwan. First, the resultsTable 2 Factors associated with the persistence of imatinib in
Characteristics Non-persistenta Pe
(n = 479) (n
Age at diagnosis, y, n (%)
≥40, 308 (64.3) 210
<40 171 (35.7) 93
Gender, n (%)
Male 281 (58.7) 185
Female 198 (41.3) 118
Charlson comorbidity score, n (%)
>0 215 (44.9) 123
=0 264 (55.1) 180
CML diagnosis, n (%)
≥2004 260 (54.3) 126
<2004 219 (45.7) 177
CML severity, n (%)
Unknown 28 (5.9) 24
Low 2 (0.4) 2 (
Moderate 378 (78.9) 251
High 71 (14.8) 26
Prior treatment, n (%)
Hydroxyurea 342 (71.4) 225
Busulfan 8 (1.7) 9 (
IFNα/Ara-C 72 (15.0) 75
Mean time to imatinib initiation, month (SD) 14.1 (19.6) 15.
Mean starting daily dose, mg/day (SD)b 362 (141) 375
Mean treatment duration, months (SD) 16.5 (16.8) 41.
HSCT post-index date, n (%) 35 (7.3) 2 (
a. Patients were considered persistent if they were taking imatinib without interruption (e
b. Excluding patients with a single imatinib claim (n = 19).
c. OR = odds ratio, each OR of the variable was adjusted by the other factors in the
Abbreviations: CML, chronic myeloid leukemia; IFNα, interferon-α; Ara-C, cytarabine;
d. t test for numerical outcomes.are consistent with the current clinical guidelines recom-
mending imatinib as first-line therapy for CML of any
stage. The use of imatinib increased rapidly between
2002 and 2004, with an increase of over 5-fold during
this time, corresponding to the introduction of imatinib
in Taiwan. We also found that the proportion of patients
with very severe CML starting imatinib decreased
significantly from 38.1% to 18.6% between 1998 and
2007, which suggests that imatinib was mostly started
in CML-CP. This may be due to the results of the
IRIS trials, which showed that the complete cytogen-
etic response rate was lower in patients with CML in
advanced phases as compared with earlier phases of
CML [6,7]. Future studies should examine the appro-
priateness of very frequent imatinib use and whether
starting treatment in earlier stages provides better
outcomes.itial therapy





(69.3) 1.4 (0.9 to 2.1) 0.15
(30.7) 1 (referent)
0.44 (0.51)
(61.1) 1.4 (0.9 to 2.1) 0.10
(38.9) 1 (referent)
1.39 (0.24)
(40.6) 0.8 (0.5 to 1.1) 0.16
(59.4) 1 (referent)
11.97(<0.001)
(41.6) 4.1 (2.2 to 7.9) <.0001
(48.4) 1 (referent)
7.60 (0.06)
(7.9) 0.6 (0.2 to 1.6) 0.20
0.7) 1.4 (0.1 to 19.0) 0.77
(82.8) 1.5 (0.8 to 3.0) 0.30
(8.6) 1 (referent)
(74.3) 0.76 (0.38) 1.8 (1.1 to 2.8) 0.02
3.0) 1.48 (0.22) 0.5 (0.1 to 2.0) 0.34
(24.8) 11.49(<0.001) 1.9 (1.1 to 3.3) 0.02
4 (19.4) 0.89 (0.37)d 1.0 (0.99 to 1.02) 0.42
(108) 1.35 (0.18) d 1.1 (0.97 to 1.34) 0.11
2 (14.2) 21.94 (<.0001) d 1.1 (1.09 to 1.13) <.0001
0.7) 18.19(<.0001) 0.1 (0.02 to 0.5) 0.01
xceeding a 60-day permissible gap) for at least 18 months since the start of therapy.
logistic regression model.
HSCT, hematopoietic stem cell transplantation.
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tional CML regimens is quite pronounced. Consistent
with the results of the European Group for Blood and
Marrow Transplantation activity survey [2], the number
of patients treated with HSCT gradually declined in our
study (from 10 cases in 2004 to 2 cases in 2007).
Although busulfan was also used before the introduction
of TKIs, its utilization remained low after the introduc-
tion of imatinib. On the other hand, we found temporal
relationship between the utilization of imatinib and
either hydroxyurea or IFNα between 2002 and 2003.
Although hydroxyurea does not appear to cure or modu-
late the progression of disease, its concomitant use with
imatinib may help to control early symptoms, particu-
larly increases in the white blood cell count. Although
IFNα is superior to hydroxyurea and busulfan in terms
of clinical outcomes [16], it was less widely used, and
the proportion of patients treated with IFNα decreased
markedly between 2003 and 2004. One explanation for
this is that IFNα is associated with considerable adverse
effects. It must be noted that some patients treated with
imatinib were also concurrently treated with other
conventional regimens in any year. The differences and
trends in utilization observed here suggest that the
choice of treatment for CML was probably influenced by
treatment responses (e.g. failure, intolerant drug adverse
effect), clinical evidence and the need for prior
authorization to use imatinib in accordance with the
NHI program at the time. The effects of using these
conventional drugs in combination with imatinib on
long term clinical outcomes remain uncertain.
Interestingly, the time from starting to discontinuing
imatinib therapy differed substantially between clinical
trials and routine clinical practice. Because the definition
of persistence in our study was linked to the length of
continued treatment, we found that a large proportion
of newly diagnosed patients were only briefly treated
with imatinib. Unlike the IRIS trial, we found that
approximately one-third (33.4%) of patients who started
imatinib therapy discontinued or interrupted treatment
within 1 year, and < 10% of patients continued imatinib
therapy for > 5 years, and 55.5% of the newly diagnosed
patients did not receive imatinib within 6 months of
diagnosis. Although some of the patients continued
imatinib for > 18 months and some for the entire treatment
period, drug interruptions caused by non-adherence, for
example, can result in failure to achieve an adequate
molecular response, and may compromise event-free
survival [17,18].
Third, previous studies have shown that the adherence
rate to imatinib therapy in clinical settings are less than
optimal. Some studies use the medication possession
rate (MPR), which is defined as the total number of days’
supply of imatinib divided by the duration of follow-upto assess medication adherence. Neoens et al. conducted
a multicenter prospective study of patients treated with
imatinib for ≥ 30 days over a 90-day period [19]. They
found that only 14.2% of the patients fully adhered to
the prescribed imatinib. Marin et al. reported that over a
1-year follow-up, 74.6% of patients had an MPR > 90%
determined using a microelectronic pill counting system
in their single-center study [20]. Wu et al. retrospec-
tively assessed MPR in patients with newly diagnosed
CML enrolling in a managed care organization [21]. In
that study, 59.1% of patients newly treated with imatinib
had an MPR ≥ 85% during the 1-year follow-up. Darkow
et al. also studied managed-care recipients diagnosed
with CML, and found that 31% of the patients had a
treatment interruption and 50% had an MPR > 95% over
1 year of follow-up [22]. Although the cutoff time used
to define non-adherence and the results of other studies
are limited to a relatively short duration of therapy
[21,22], poor compliance to imatinib therapy may
actually increase healthcare costs and prevent optimal
clinical outcomes.
Persistence adds the dimension of time to the analysis
and represents the time from the initial filling of the
imatinib prescription until the patient discontinues
(or interrupts) prescription refills [13]. We noted an
increased likelihood of non-persistence to imatinib
within 1 year of CML diagnosis in patients diagnosed
earlier than 2002. This may be due to the need for
prior authorization for imatinib according to the NHI
program, which was necessary between January 2002
and December 2003. The requirement for prior
authorization probably created an unintended barrier
that affected the physician’s decisions and likelihood
of continuing mediation during the initial period of
treatment. We found that better medication persistence
at the beginning of imatinib therapy (≧ 18 months) was
associated with a longer treatment duration during the
follow-up and prior therapies with hydroxyurea and IFNα
(or Ara-C). There are several possible reasons for this
finding. For example, the patients are more likely to
experience intolerable adverse effects or poor efficacy, or
the patient discontinue for symptomatic relief. However,
the severity of CML at diagnosis and the time of starting
treatment after diagnosis were not significantly associated
with persistence in our study. Usually, patients with
severe or complex disease are more likely to start therapy
sooner after diagnosis and are more likely to be adherent
(for example, prior therapies with hydroxyurea, IFNα or
Ara-C) than those with asymptomatic disease. However,
it is possible that patients with advanced disease are more
likely to suffer severe hematologic responses that require
treatment discontinuation, and hence incur additional
health costs [21,22]. These hypotheses should be investi-
gated in this population.
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CML. Current guidelines recommend imatinib as first-line
therapy for CML-CP, and should also be considered as a
treatment option for CML-AP, CML-BC or CML-CP after
failure of IFNα therapy [14,15]. However, a substantial
proportion of patients may need clinical support to persist
with therapy and hence achieve the optimal benefits
of imatinib. As described by other investigators, non-
adherence to therapy may be represent an interaction
between patient, healthcare professional, economic, and
healthcare system factors [19,23]. Persistence to initial
therapy should be an achievable target in routine clinical
practice for managing CML in all stages. As imatinib is
fully reimbursed by the NHI program, interventions are
needed to enhance treatment persistence. Such interven-
tions should encourage physicians to regularly monitor
and continue to follow-up patients indicated for and start-
ing imatinib therapy. Unlike many parenteral anticancer
medicines, patients taking oral imatinib do so on their
own. Therefore, we should endeavor to identify patients at
high risk of non-persistence. We may be able to provide
them and their caregivers with appropriate education to
better understand the clinical benefits of persistence and
adherence to therapy [19], even though their disease may
be improving during treatment. Supportive activities and
individual interventions aimed at breaking down the
barrier to adherence may reinforce medication persistence
and adherence.
A limitation to our study is the lack of laboratory data
that can be used to assess the severity of CML in newly
diagnosed patients. To overcome this limitation, we used
the Medstat disease staging algorithm, which is widely
applied to measure the different phases of disease and
analyze resource utilization, reimbursement, and quality
of care. Compared with neighboring Asian countries
[12], ≤ 20% of the new CML diagnoses were CML-AP
(mean, 11%; range, 0–30%) and ≤ 15% were CML-BC
(mean, 5%; range, 0–20%). Thus, our data are
generalizable to the Asia-Pacific region. Unfortunately,
because of the aggregated nature of hospitalization and
outpatient visit claims, the duration of drug prescription
and daily dosing frequency in medical records cannot be
accurately assessed using claims data alone. We tried to
overcome this limitation by including the mean daily
dose in patients with at least two claims for imatinib.
The mean starting daily dose for some non-persistent
patients was much lower than the recommended dose of
400 mg. This may be because these patients refilled the
prescription for imatinib after a long gap (e.g., > 60 days)
and tended to have a short duration of treatment (< 1 year).
Therefore, the starting dose in these patients is likely to be
underestimated. Consequently, the association between the
mean starting dose and medication persistence may be
biased towards a high starting dose. Another limitation ofusing claims data is that we cannot confirm whether the
drug was actually taken or taken as prescribed. Finally,
patient-related factors (e.g., cognitive ability, lack of family
support, and limited understanding of the need for long-
term therapy) may influence adherence, but could not be
accounted for in this study.
Conclusions
This population-based observational study revealed that
the use of imatinib to treat newly diagnosed CML has
increased over the last decade, principally because of
increased prescription in patients with fewer comorbidities
and less-severe CML. Although imatinib is widely available,
does not need prior authorization anymore, and is fully
reimbursed, a large number of patients starting imatinib
discontinued therapy within a short time or did not persist
with therapy for the critical initial therapeutic period. To
achieve optimal therapeutic outcomes, it is essential that
the patient persists with therapy, which relies on ongoing
monitoring, encouragement, education, and regular follow-
up. From the healthcare system perspective, further studies
are needed to evaluate methods to improve persistence as
well as outcomes, both effectiveness and risks associated
with long-term imatinib therapy.
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